307 related articles for article (PubMed ID: 25012839)
1. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.
Takiar V; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM
Pract Radiat Oncol; 2014; 4(4):e189-94. PubMed ID: 25012839
[TBL] [Abstract][Full Text] [Related]
2. A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma.
Takiar V; Voong KR; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM
Pract Radiat Oncol; 2015; 5(3):e169-e176. PubMed ID: 25423888
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience.
Perri P; Fiorica F; D'Angelo S; Lamberti G; Parmeggiani F; Martini A; Carpenteri F; Colosimo C; Micucci M; Perazzini L; De Gugliemo E; Berretta M; Sebastiani A; Cartei F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1919-24. PubMed ID: 23242717
[TBL] [Abstract][Full Text] [Related]
4. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.
Barker CA; Francis JH; Cohen GN; Marr BP; Wolden SL; McCormick B; Abramson DH
Brachytherapy; 2014; 13(6):584-90. PubMed ID: 24880583
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
6. Tumor control, eye preservation, and visual outcomes of ruthenium plaque brachytherapy for choroidal melanoma.
Marconi DG; de Castro DG; Rebouças LM; Bernardes Gil GO; Fogaroli RC; Conte Maia MA; Gobo Silva ML; Assis Pellizzon AC; Motono Chojniak MM
Brachytherapy; 2013; 12(3):235-9. PubMed ID: 22436517
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium-106 plaque brachytherapy for uveal melanoma.
Tarmann L; Wackernagel W; Avian A; Mayer C; Schneider M; Winkler P; Langmann G
Br J Ophthalmol; 2015 Dec; 99(12):1644-9. PubMed ID: 25979763
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
11. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
12. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
Toivonen P; Kivelä T
Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
[TBL] [Abstract][Full Text] [Related]
13. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.
Summanen P; Immonen I; Kivelä T; Tommila P; Heikkonen J; Tarkkanen A
Br J Ophthalmol; 1996 Aug; 80(8):732-9. PubMed ID: 8949719
[TBL] [Abstract][Full Text] [Related]
14. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy.
Papageorgiou KI; Cohen VM; Bunce C; Kinsella M; Hungerford JL
Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528
[TBL] [Abstract][Full Text] [Related]
15. Retina dose as a predictor for visual acuity loss in
Heilemann G; Fetty L; Blaickner M; Nesvacil N; Zehetmayer M; Georg D; Dunavoelgyi R
Radiother Oncol; 2018 Jun; 127(3):379-384. PubMed ID: 29452902
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma.
Lommatzsch PK; Werschnik C; Schuster E
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):129-37. PubMed ID: 10766281
[TBL] [Abstract][Full Text] [Related]
17. Ruthenium-106 brachytherapy.
Pe'er J
Dev Ophthalmol; 2012; 49():27-40. PubMed ID: 22042011
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?
Razzaq L; de Keizer RJ
Br J Ophthalmol; 2010 Nov; 94(11):1549-50. PubMed ID: 20516146
[No Abstract] [Full Text] [Related]
19. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.
Pagliara MM; Tagliaferri L; Azario L; Lenkowicz J; Lanza A; Autorino R; Caputo CG; Gambacorta MA; Valentini V; Blasi MA
Brachytherapy; 2018; 17(2):432-438. PubMed ID: 29275868
[TBL] [Abstract][Full Text] [Related]
20. Use of Ruthenium-106 Brachytherapy for Iris Melanoma: The Scottish Experience.
Agraval U; Sobti M; Russell HC; Lockington D; Ritchie D; Cauchi P; Kemp EG; Chadha V
Br J Ophthalmol; 2018 Jan; 102(1):74-78. PubMed ID: 28600302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
